Trust the Evidence

Trust the Evidence

Share this post

Trust the Evidence
Trust the Evidence
Investigating the Miracle Biologic Lecanemab for Alzheimer's Disease - Part 2

Investigating the Miracle Biologic Lecanemab for Alzheimer's Disease - Part 2

Lecanemab’s effectiveness evidence base

Tom Jefferson's avatar
Carl Heneghan's avatar
Tom Jefferson
and
Carl Heneghan
Aug 27, 2024
∙ Paid
64

Share this post

Trust the Evidence
Trust the Evidence
Investigating the Miracle Biologic Lecanemab for Alzheimer's Disease - Part 2
15
8
Share

Okay, folks, let’s start from…..the start. We two geezers like having our ducks lined up before commenting, as you all know from the Antivirals and Comirnaty series of posts. So the start of the line-up is: how many and what investigations were carried out on the wonder Monoclonal Antibody (MAB) Lecanemab for Early Alzheimer's Disease (AD)? 

Share

The Japanese regulator PMDA provides the answer:

As usual (you have to get used to it), we have the nth acronym: OLE, in this case—open Label Extension.

We have phases I, II, and III trials; somehow, the open-label extension is tucked into the last two, 201 and 301. 

The sobriquet “core” is strange. Some pharmaceutical companies use the term “pivotal” when they propose the trial, which, according to them, best supports their request for licensing. 

Regulators and pharma have long tried to standardise their lexicon, but there may be the odd slip. We assume “core” means “pivotal”. Strange that a phase II trial should be called that, but let’s stop splitt…

Keep reading with a 7-day free trial

Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 Carl Heneghan
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share